Comparative Pharmacology
Head-to-head clinical analysis: KAON CL versus MICRO K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAON CL versus MICRO K.
KAON CL vs MICRO-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Potassium is the principal intracellular cation, essential for maintaining cellular tonicity, electrical neutrality, and enzymatic reactions. It modulates neuromuscular transmission, cardiac contractility, and acid-base balance.
Oral: 20 mEq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 mEq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Oral: 20-40 mEq (1-2 capsules) two to four times daily; maximum 100 mEq/day. Each capsule contains 8 mEq (600 mg) of potassium chloride in a wax matrix extended-release formulation.
None Documented
None Documented
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Not applicable; potassium is an electrolyte with no true elimination half-life; whole-body turnover half-life is approximately 12-24 hours, clinically relevant for dosing intervals.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Renal: approximately 90% of absorbed potassium is excreted in urine; biliary/fecal: less than 10% eliminated via feces.
Category C
Category C
Electrolyte Supplement (Potassium)
Electrolyte Supplement (Potassium)